FindTrial
Sign In

Effects Of Strength Training Versus Endurance Training On Hepatic Steatosis, Function, Central Adiposity And Quality Of Life In Individuals With Non-Alcoholic Fatty Liver Disease

Effects Of Strength Training Versus Endurance Training On Hepatic Steatosis, Function, Central Adiposity And Quality Of Life In Individuals With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/103972
Enrollment
36
Registered
2026-02-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Strength Training (Calisthenics): Participants will receive a graded strength training intervention consisting of structured calisthenics exercises targeting major muscle groups. The pr

Sponsors

Krupa Prabhu
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individuals of all genders aged 25-50 years diagnosed with Non-Alcoholic Fatty Liver Disease by a Gastroenterologist. 2. Ultrasound confirmed Grade 1-2 hepatic steatosis. 3. Body Mass Index (BMI) between 25-35 kg per m2, indicating overweight or class 1 obesity. 4. Elevated or borderline liver enzyme levels ( ALT and or or AST), ALT greater than 56 units per liter and or or AST greater than 40 units per liter. 5. Willingness to participate and provide Informed Consent.

Exclusion criteria

Exclusion criteria: 1. Alcohol intake greater than 21 units per week (men) or greater than 14 units per week (women). 2. Other liver diseases or cirrhosis 3. Uncontrolled cardiovascular, respiratory, or endocrine disorders. 4. Participants with a history of regular exercise 5. Musculoskeletal limitations preventing exercise. 6. Use of hepatotoxic or lipid-lowering medications (e.g., corticosteroids, statins) 7. Pregnancy or lactating

Design outcomes

Primary

MeasureTime frame
1. Hepatic steatosis assessed using ultrasonography (USG) through standardized grading of liver echogenicity. 2. Hepatic function evaluated using serum liver enzyme levels (ALT and AST) obtained through laboratory blood tests.Timepoint: 1. Hepatic steatosis assessed using ultrasonography (USG) through standardized grading of liver echogenicity at baseline and end of 8 weeks. 2. Hepatic function evaluated using serum liver enzyme levels (ALT and AST) obtained through laboratory blood tests at baseline and end of 8 weeks.—

Secondary

MeasureTime frame
1. Central adiposity assessed using the waist hip ratio (WHR) measured with a non-elastic measuring tape. 2. Quality of life assessed using the Short Form-36 (SF-36) questionnaire.Timepoint: 1. Central adiposity (waist hip ratio) will be assessed pre-intervention & post-intervention, at baseline & end of 8 weeks. 2. Quality of life (SF-36) will be assessed pre-intervention & post-intervention, at baseline & end of 8 weeks.—

Countries

India

Contacts

Public ContactDr Vijay Kage

KAHER Institute of Physiotherapy, Belagavi

vijaykage@yahoo.in9845271899

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026